Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease
The University of Texas Medical Branch, Galveston
490 participants
Aug 26, 2025
INTERVENTIONAL
Conditions
Summary
The purpose of the study is to determine which combination of neuromuscular blocking agent and reversal agent is safer to use during anesthesia for patients with chronic kidney disease. The main question it aims to answer is "The use of Cisatracurium with neostigmine leads to less post-operative pulmonary complications than Rocuronium with sugammadex."
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Will be assessing neuromuscular blockade with rocuronium and reversal with sugammadex
Will be assessing neuromuscular blockade with neostigmine and reversal with neostigmine
Will be assessing neuromuscular blockade with rocuronium and reversal with sugammadex
Will be assessing neuromuscular blockade with neostigmine and reversal with neostigmine
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07203287